Skip to Content

Clinical Trials Detail

A PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Objective
This is a clinical trial of pomalidomide that will be administered by mouth which is investigational and bortezomib and low-dose dexamethasone that will be administered by I.V. and mouth and is standard of care.
IRB Protocol Number
13-2056
Principal Investigator(s)
CLAY SMITH

Cancer Trials

  • Multiple Myeloma/Plasma Cell Tumors
Sponsor(s)
Celgene Corporation
Contact
LEIGH WALZER at 720-848-0736
or LEIGH.WALZER@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to when your disease worsens. A follow up period will consist of phone contact, physician contact, or clinic visit. // Eligibility criteria include but are not limited to 18 years or older with multiple myeloma.